These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


79 related items for PubMed ID: 7682860

  • 1. Brief induction chemotherapy followed by involved-field irradiation for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma.
    Ohnoshi T, Hayashi K, Mizuta J, Tagawa S, Matsutomo S, Saito S, Kawashima K, Akagi T, Kimura I.
    Int J Hematol; 1993 Jan; 57(1):61-6. PubMed ID: 7682860
    [Abstract] [Full Text] [Related]

  • 2. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.
    Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI.
    N Engl J Med; 1998 Jul 02; 339(1):21-6. PubMed ID: 9647875
    [Abstract] [Full Text] [Related]

  • 3. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
    Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, Rodriguez MA, Ha CS, Smith TL, Ayala A, Hess M, Cox JD, Cabanillas F, McLaughlin P.
    J Clin Oncol; 2003 Jun 01; 21(11):2115-22. PubMed ID: 12775737
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study.
    Bernard M, Cartron G, Rachieru P, LeMevel A, Branger B, Le Maignan C, Berthou C, Ghandour C, Delwail V, Milpied N, Cassasus P, Celigny PS, Guyotat D, Lamy T, Desablens B, French GOELAMS Group.
    Haematologica; 2005 Jun 01; 90(6):802-9. PubMed ID: 15951293
    [Abstract] [Full Text] [Related]

  • 5. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 May 01; 21(9):1734-9. PubMed ID: 12721249
    [Abstract] [Full Text] [Related]

  • 6. Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach.
    De Sanctis V, Martelli M, Anticoli AP, Caronna R, Chirletti P, Giovannini M, Santarelli M, Enrici RM, Mandelli F.
    Anticancer Res; 2001 May 01; 21(6A):4169-72. PubMed ID: 11911313
    [Abstract] [Full Text] [Related]

  • 7. A prospective study of reduced-dose three-course CHOP followed by involved-field radiotherapy for patients 70 years old or more with localized aggressive non-Hodgkin's lymphoma.
    Shikama N, Oguchi M, Isobe K, Nakamura K, Tamaki Y, Hasegawa M, Kodaira T, Sasaki S, Kagami Y, Japan Radiation Oncology Group (JAROG).
    Int J Radiat Oncol Biol Phys; 2006 Sep 01; 66(1):217-22. PubMed ID: 16814951
    [Abstract] [Full Text] [Related]

  • 8. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G, Coser P, Congiu AM, Salvagno L, De Souza C, Sertoli MR, Olivieri A, Chisesi T, Rubagotti A, Truini M, Contu A, Porcellini A, Zambaldi G, Nati S, Marino G, Rizzoli V.
    Haematologica; 2000 Feb 01; 85(2):160-6. PubMed ID: 10681723
    [Abstract] [Full Text] [Related]

  • 9. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease.
    Viviani S, Bonfante V, Santoro A, Zanini M, Devizzi L, Di Russo AD, Soncini F, Villani F, Ragni G, Valagussa P, Bonadonna G.
    Cancer J Sci Am; 1999 Feb 01; 5(5):275-82. PubMed ID: 10526668
    [Abstract] [Full Text] [Related]

  • 10. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
    Nishioka T, Tsuchiya K, Nishioka S, Kitahara T, Ohmori K, Homma A, Aoyma H, Shindoh M, Shirato H.
    Int J Radiat Oncol Biol Phys; 2004 Nov 01; 60(3):847-52. PubMed ID: 15465202
    [Abstract] [Full Text] [Related]

  • 11. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.
    Haematologica; 2000 Mar 01; 85(3):263-8. PubMed ID: 10702814
    [Abstract] [Full Text] [Related]

  • 12. Treatment results of tonsillar lymphoma: a 10-year experience.
    Mohammadianpanah M, Omidvai S, Mosalei A, Ahmadloo N.
    Ann Hematol; 2005 Apr 01; 84(4):223-6. PubMed ID: 15042316
    [Abstract] [Full Text] [Related]

  • 13. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 Oct 01; 21(19):3601-8. PubMed ID: 12913100
    [Abstract] [Full Text] [Related]

  • 14. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
    Schenkein DP, Roitman D, Miller KB, Morelli J, Stadtmauer E, Pecora AL, Cassileth P, Fernandez H, Cooper BW, Kutteh L, Lazarus HM.
    Biol Blood Marrow Transplant; 1997 Oct 01; 3(4):210-6. PubMed ID: 9360783
    [Abstract] [Full Text] [Related]

  • 15. Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy.
    Ohga S, Nakamura K, Shioyama Y, Sasaki T, Urashima Y, Terashima H, Honda H.
    Radiat Med; 2005 May 01; 23(3):156-61. PubMed ID: 15940061
    [Abstract] [Full Text] [Related]

  • 16. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B, Jancić-Nedeljkov R, Sretenović M, Milivojević G, Janković S, Petrović M.
    Srp Arh Celok Lek; 1998 May 01; 126(9-10):345-8. PubMed ID: 9863405
    [Abstract] [Full Text] [Related]

  • 17. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
    Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, Petit J.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):501-8. PubMed ID: 15145169
    [Abstract] [Full Text] [Related]

  • 18. [Trial of front-line intensive chemotherapy followed by peripheral blood stem cell transplantation in high-intermediate and high risk non-Hodgkin's lymphoma patients].
    Motomura S, Hashimoto C, Kodama F, Maruta A, Sakai R, Fujita H, Tomita N, Fujisawa S, Harano H, Koharazawa H, Fujimaki K, Kanamori H, Ishigatsubo Y.
    Rinsho Ketsueki; 2005 May 01; 46(5):350-7. PubMed ID: 16444968
    [Abstract] [Full Text] [Related]

  • 19. [Chemotherapy for non-Hodgkin's lymphoma].
    Kuraishi Y, Usui N, Dobashi N.
    Gan To Kagaku Ryoho; 1998 Dec 01; 25(14):2210-6. PubMed ID: 9881077
    [Abstract] [Full Text] [Related]

  • 20. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
    Hausdorff J, Davis E, Long G, Hoppe R, van der Pas M, Lassman C, Kamel O, Jacobs C.
    Cancer J Sci Am; 1997 Dec 01; 3(5):303-11. PubMed ID: 9327155
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 4.